Sarcoma  >>  retaspimycin (IPI-504)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
retaspimycin (IPI-504) / Infinity Pharma
NCT00969917: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Withdrawn
2
0
US
IPI-504
Infinity Pharmaceuticals, Inc.
Dedifferentiated Liposarcoma
12/10
12/10

Download Options